# US 2013/0158126 A1 · Cannabinoid quinone derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158126 A1
- Document ID: US20130158126A1
- Status: Published application
- Kind: A1
- Application number: 13/636,214
- Filed: 2010-03-26
- Published: 2013-06-20
- Earliest claimed: 2010-03-26
- Assignees: Vivacell Biotechnology Espana, S.L.
- Inventors: Eduardo Muñoz Blanco; Giovanni Appendino; María Luz Bellido Cabello De Alba
- Web page: https://patentgrep.com/patent/US20130158126A1

## CPC

- C07C 50/28: with monocyclic quinoid structure
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 50/38: containing —CHO or non—quinoid keto groups
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Cannabinoid quinone derivatives. The present invention refers to cannabinoid quinone derivatives to be used as medicaments, particularly as PPAR gamma (PPARg) agonists for treating diseases which etiology is based on an impaired PPARg function as transcription factor i.e. PPARg-related diseases.

## Claims

### Claim at position 1

-14. (canceled)

### Claim 15

Compound characterized by having the formula (VI) or derivatives thereof:

### Claim 16

Method for treating PPARg-related diseases that comprises the administration to the patient of an effective amount of a pharmaceutical composition comprising a compound of Formula (VI) or derivatives thereof:

### Claim 17 (depends on 16)

Method, according to claim 16, wherein PPARg-related diseases is selected from: inflammatory diseases, metabolic diseases and type II diabetes.

### Claim 18 (depends on 16)

Method, according to claim 16, wherein PPARg-related diseases is a metabolic disease selected from: hypertension, hypertrigliceridemia, hypercholesterolemia (HDL-C) or obesity.

### Claim 19 (depends on 17)

Method, according to claim 17, wherein PPARg-related diseases is a metabolic disease selected from: hypertension, hypertrigliceridemia, hypercholesterolemia (HDL-C) or obesity.

### Claim 20 (depends on 16)

Method, according to claim 16, wherein PPARg-related diseases is an inflammatory diseases selected from: atherosclerosis, inflammatory bowel diseases, rheumatoid arthritis, liver fibrosis, nephropathy, psoriasis, skin wound healing, skin regeneration, pancreatitis, gastritis, neurodegenerative disorders or cancer.

### Claim 21 (depends on 17)

Method, according to claim 17, wherein PPARg-related diseases is an inflammatory diseases selected from: atherosclerosis, inflammatory bowel diseases, rheumatoid arthritis, liver fibrosis, nephropathy, psoriasis, skin wound healing, skin regeneration, pancreatitis, gastritis, neurodegenerative disorders or cancer.

### Claim 22 (depends on 15)

Pharmaceutical composition comprising at least the compound of claim 15, and any suitable acceptable excipient or carrier.
